Arnaud BEURDELEY

En résumé

Entreprises

• Endodiag - Directeur scientifique

  2016 - maintenant

• InnaVirVax - Chef de projets

  Évry 2014 - 2016 En charge de la logistique de l'étude clinique de Phase II et des études de R&D associées.

• XenTech - Chef de Projet

  2005 - 2013 www.xentech.fr
  
  XenTech® is a spin-off of the Institut Curie, the largest French cancer research institute, where its platform has been developed and scientifically validated during the last 10 years.
  With one of the world’s largest collection of clinically relevant human tumor xenograft models, XenTech® reliably evaluates drug candidates, filling the gap between current preclinical models and clinical studies.
  
  More predictive preclinical models facilitate therapeutic innovation in oncology
  
  Ethically and economically, reducing late attrition is of major importance in the oncology therapeutic area.
  The success of oncology compounds beyond Phase 1 development largely relies on the molecular relevance of animal models used for preclinical pharmacology studies.
  Panels of tumor models with clinically relevant characteristics defined by genomics and proteomics optimize the chances of success in clinical trials by :
  
  - excluding ineffective drug candidates early on
  - correctly identifying responsive cancer types
  - identifying synergistic, additive or antagonistic therapeutic combinations
  - allowing biomarker discovery studies for patient stratification in subsequent clinical trials.
  
  XenTech® experimental platform is based on large panels of well-characterized human tumors directly xenografted onto nude rodents, allowing clinically relevant preclinical studies.
  
  Preclinical platform
  Our staff has conducted preclinical oncology studies for over 10 years.
  We offer our expertise for the development of your leads:
  
  - customized approach with a dedicated project manager
  - consulting for protocol establishment
  - high-content molecular database for target expression screening,tumor selection and proof-of-concept studies
  - in vivo and in vitro assays
  - tolerance and efficacy studies
  - biomarker discovery programs
  
  Facilities
  XenTech® is located in the south of Paris, at Genopole, France’s largest biocluster.
  In vivo studies are conducted at the Center for Exploration and Experimental Functional research (CERFE), a recent SOPF animal facility meeting the latest ethical and technical standards.
  Ethical
  Studies are based on strict scientific and ethical criteria. Confidentiality is guaranteed
  
  In vivo assays
  Species
  Mice come from certified suppliers with Specific and Opportunistic Pathogen Free (SOPF) status.
  Treatments
  All experiments are performed by experienced technicians under the direct supervision of a dedicated project manager.
  Animal care and housing follow current ethical guidelines.
  Single or combination treatments, with reference chemotherapeutic agents or customer test drugs are routinely performed.
  Follow-up and services
  Animals are followed-up on a daily basis (body weight, general health) with specific measurements adapted to protocols.
  Sampling:
  If included in the protocol, XenTech® can take unique or repeated samples of biological fluids (blood, serum, plasma) or organs for biological assays.
  Results and reporting
  Detailed reports contain all commonly accepted endpoints, contract-determined endpoints and high quality graphics. Each report includes all experimental raw datas, easily interpretable tables and figures, and can be delivered under electronic or hard copy format. Interim reports are provided, ensuring strong interactions with customers.
  
  In vitro screening
  In addition to in vivo assays, we can perform high-throughput in vitro assays with permanent tumor cell lines (cytotoxicity, cytostasis, cell cycle distribution, apoptosis) as a primary anti-tumor activity screening of your lead compound collections.
  
  XenTech® proposes fee-for service efficacy studies as well as research collaborations to co-develop theranostics.

• ALINEA RH - Chargé de Recrutement

  2003 - 2004 ALINEA RH est un cabinet de recrutement spécialisé dans le domaine de la Santé Humaine. Il se compose de 3 départements : Médical, Paramédical et Biotechnologie & Industrie Pharmaceutique
  En tant que responsable du département "Biotechnologie & Industrie Pharmaceutique" j'ai mis en place et géré les bases de données Clients et Candidats, j'étais en charge de la prospection commerciale pour mon département.
  Pour l'activité Recrutement, j'ai travaillé pour une dizaine de clients ( 30 personnes recrutées sur différents postes allant du technicien de maintenance au manager avant projet en cardiologie).

• MOLECULAR ENGINES LABORATORIES - Ingénieur

  Будапешт 2001 - 2002 Responsable d'une plate forme de PCR en Temps réel pour la mise en évidence de différentiels d'expression de gènes entre une lignée cellulaire tumorale et la lignée n'exprimant plus le caractère tumoral.
  400 gènes étudiés et validés et publiés dans une revue internationale à grand comité de lecture

• Laboratoire d'Oncologie Médicale - Ingénieur d'études

  2001 - 2001 Mise au point de tests de détection des mutations ponctuelles (SNiPs) dans la séquence génomique des enzymes intervenant dans le métabolisme des xénobiotiques et dans la réparation de l'ADN

Formations

• Université Paris 5 René Descartes

  Paris 2006 - 2006 DU Expérimentation animale Niveau I

• HEC

  Jouy En Josas 2005 - 2006

• Conservatoire National Des Arts Et Métiers IIM - Institut Internation du Management

  Paris 2001 - 2003

• Ecole Pratique Des Hautes Etudes

  Paris 1998 - 2001

• Université Rouen Haute Normandie

  Mont St Aignan 1994 - 1998

• Université Rouen Haute Normandie (Rouen)

  Rouen 1992 - 1994

• Lycée Jean Baptiste De La Salle

  Rouen 1984 - 1992

Réseau

• Boris FRANCOIS

• Catherine DUBOIS

• Gael STEPHANT

• Hélène VIDAL-MALANDAIN

• Marie-Charlotte COLIN

• Mathieu GASTAL

• Raphael LINOSSIER

  Aurior (Paris)

• Tamara NORA

• Valérie LEDAUPHIN